Revvity, Inc. (RVTY) announced a strategic collaboration with Profluent, resulting in a simplified access for customers to a therapeutically relevant base editing toolkit. The new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing.
The company said the combination of the Pin-point platform and a curated selection of Profluent's adenine deaminases are available from Revvity through bundled licensing to significantly expand the number of disease-related mutations that could be addressed using the Pin-point platform and accelerate adoption by therapeutic developers.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.